Gemcitabine with nab-paclitaxel schedule for metastatic pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 study tests whether a specific timing (schedule) of two chemotherapy drugs—gemcitabine and nab-paclitaxel—can work better for metastatic pancreatic cancer. It may help patients by improving how the drugs are delivered while watching for side effects and tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed pancreatic duct cancer that has spread (not a pancreas islet-cell tumor).
- Your scans show at least one measurable metastatic tumor on CT or MRI.
- You have not had chemotherapy or investigational treatment for metastatic pancreatic cancer before (with limited exceptions for some past radiation/chemo timing).
- Your blood counts and liver function are strong enough for treatment (specific lab thresholds for neutrophils, platelets, hemoglobin, AST/ALT, and bilirubin).
- You can do daily activities at a moderate level (Karnofsky 60+ or ECOG 0–2).
- If you can become pregnant or impregnate someone, you must use very reliable birth control during treatment and for 3 months after; pregnancy test must be negative if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests gemcitabine chemotherapy in people with metastatic pancreatic cancer who cannot take FOLFIRINOX. It aims to see how well gemcitabine works based on a specific tumor marker called GemCore.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.